Drugs / Kamada Anti-SARS-CoV-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04550325 | Aug → Nov 2020 | COVID-19, viral pneumonia | Kamada, Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-03-31 | Kamada, Ltd. | Results Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for Coronavirus Disease (COVID-19) kamada.com ↗
Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced top-line results from its Phase 1/2 open-label, single-arm, multi-center clinical trial in Israel of the Company’s anti-SARS-CoV-2 plasma-derived hyperimmune globulin (IgG) treatment for coronavirus disease (COVID-19). |
| 2020-09-08 | Kamada, Ltd. | Results Kamada Announces Completion of Enrollment and Initial Interim Results from its Phase 1/2 Clinical Trial in Israel of its Plasma-Derived Hyperimmune Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19) kamada.com ↗
Symptoms improvement was observed in 11 of the 12 patients within 24 to 48 hours from treatment. |
All press releases naming this drug 3 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kamada Anti-SARS-CoV-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04550325 ↗ |
| Known as | Anti-SARS-CoV-2 | “Anti-SARS-CoV-2 is a preparation of immune gamma globulin manufactured from convalescent plasma of COVID-19 recovered patients, using Kamada's proprietary purification methods” NCT04550325 ↗ |
| Modality | Protein / enzyme biologic | “Immune gamma globulin (IgG) preparation” NCT04550325 ↗ |
| Route | Intravenous | “given as an intravenous infusion” NCT04550325 ↗ |